Baidu
map

JACC:再入院减少计划可减少心梗和心衰30天再住院率

2019-07-22 不详 MedSci原创

医院再入院减少计划(HRRP)可以减少急性心梗(AMI)和心衰(HF)的30天再住院率。本研究的目的旨在探究该30天再住院率的减少是否与患者推迟住院或再住院时间超过30天相关。本研究纳入分析了3256家实施HRRP计划的医院,对于AMI患者,出院后1-30天和31-60天的再住院率分别为19.6% ([IQR]: 16.7%-22.9%) 和7.8% (IQR: 6.5%-9.4%),对于心衰患者

医院再入院减少计划(HRRP)可以减少急性心梗(AMI)和心衰(HF)的30天再住院率。本研究的目的旨在探究该30天再住院率的减少是否与患者推迟住院或再住院时间超过30天相关。

本研究纳入分析了3256家实施HRRP计划的医院,对于AMI患者,出院后1-30天和31-60天的再住院率分别为19.6% ([IQR]: 16.7%-22.9%) 和7.8% (IQR: 6.5%-9.4%),对于心衰患者,分别为23.0% (IQR: 20.6%-25.3%)和11.4% (IQR: 10.2%-12.6%),对于肺炎患者,分别为17.5% (IQR: 15.4%-19.8%)和8.3% (IQR: 7.3%-9.3%)。大部分的日再住院率均随着时间推移而降低,且30天的再住院率的回归分析没有中断。

研究结果显示,没有证据表明临床医师在出院后30天内采取了专门推迟入院或影响死亡率的策略,因此医院再入院减少计划确实可以减少心梗和心衰的30天再住院率。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663237, encodeId=0f00166323e05, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Sat Apr 11 01:07:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854452, encodeId=6050185445286, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 04 23:07:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977812, encodeId=204d19e7812f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Feb 11 10:07:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370857, encodeId=61463e0857b9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Tue Aug 06 11:53:31 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370646, encodeId=5cfd3e064684, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Fri Aug 02 10:01:07 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326277, encodeId=a9a113262e75e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 24 07:07:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663237, encodeId=0f00166323e05, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Sat Apr 11 01:07:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854452, encodeId=6050185445286, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 04 23:07:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977812, encodeId=204d19e7812f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Feb 11 10:07:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370857, encodeId=61463e0857b9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Tue Aug 06 11:53:31 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370646, encodeId=5cfd3e064684, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Fri Aug 02 10:01:07 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326277, encodeId=a9a113262e75e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 24 07:07:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-09-04 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663237, encodeId=0f00166323e05, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Sat Apr 11 01:07:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854452, encodeId=6050185445286, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 04 23:07:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977812, encodeId=204d19e7812f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Feb 11 10:07:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370857, encodeId=61463e0857b9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Tue Aug 06 11:53:31 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370646, encodeId=5cfd3e064684, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Fri Aug 02 10:01:07 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326277, encodeId=a9a113262e75e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 24 07:07:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1663237, encodeId=0f00166323e05, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Sat Apr 11 01:07:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854452, encodeId=6050185445286, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 04 23:07:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977812, encodeId=204d19e7812f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Feb 11 10:07:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370857, encodeId=61463e0857b9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Tue Aug 06 11:53:31 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370646, encodeId=5cfd3e064684, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Fri Aug 02 10:01:07 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326277, encodeId=a9a113262e75e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 24 07:07:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-08-06 无一

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1663237, encodeId=0f00166323e05, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Sat Apr 11 01:07:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854452, encodeId=6050185445286, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 04 23:07:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977812, encodeId=204d19e7812f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Feb 11 10:07:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370857, encodeId=61463e0857b9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Tue Aug 06 11:53:31 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370646, encodeId=5cfd3e064684, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Fri Aug 02 10:01:07 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326277, encodeId=a9a113262e75e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 24 07:07:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-08-02 无一

    真好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1663237, encodeId=0f00166323e05, content=<a href='/topic/show?id=91a330610e0' target=_blank style='color:#2F92EE;'>#再住院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30610, encryptionId=91a330610e0, topicName=再住院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=515025593328, createdName=12498974m59暂无昵称, createdTime=Sat Apr 11 01:07:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854452, encodeId=6050185445286, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 04 23:07:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977812, encodeId=204d19e7812f8, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Feb 11 10:07:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370857, encodeId=61463e0857b9, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Tue Aug 06 11:53:31 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370646, encodeId=5cfd3e064684, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f24085546, createdName=无一, createdTime=Fri Aug 02 10:01:07 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326277, encodeId=a9a113262e75e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jul 24 07:07:00 CST 2019, time=2019-07-24, status=1, ipAttribution=)]

相关资讯

JACC:利妥昔单抗可增加心脏移植术后患者移植物血管病变

CTOT-11临床研究是一项关于心脏移植(HTX)术后患者的多中心随机双盲对照试验,本研究的目的旨在探究B细胞消耗疗法能否减轻心脏移植术后心脏移植血管病变。本研究将163名HTX患者随机分成利妥昔单抗治疗组和安慰剂组,主要终点事件是血管内超声测量的从基线到术后1年动脉粥样硬化体积百分比(PAV)的变化。研究开始时两组患者之间无明显差异,有86名患者在入组时和术后1年接受了血管内超声检测(49名为利

Obesity:非酒精性脂肪肝病严重威胁代谢健康

非酒精性脂肪肝病(NAFLD)目前已经成为一项全球流行性疾病,预计影响全球约25%~44%的人口。近期发表的一项基于韩国人群的队列研究显示NAFLD患者与那些有健康肝脏的人相比,更容易出现代谢不健康状态。该研究发表在近期的obesity上。

Clinical Chemistry:铁代谢、Hepcidin和心血管死亡率的关系?

贫血是冠心病(CAD)和死亡率的一个危险因素,而目前关于铁代谢对于其的作用仍有争议。 本研究分析了中位随访时间为9.9年的冠状动脉造影患者的铁代谢及其与心血管死亡和总死亡率的关系。在1480例冠心病稳定患者和682例经血管造影排除明显冠心病的患者中测定血红蛋白和铁水平。 研究结果显示,Multivariate-adjusted风险比率(小时)的总死亡率最低四分位数的铁、转铁蛋白饱和度、

盘点:JACC七月第二期研究一览

1.老年低心血管风险的预测因子的探索 · 2019-07-21

-->

JACC:伊多沙班和华法林对房颤伴肝脏疾病史患者的影响研究

肝脏疾病会增加栓塞和出血风险,且会在直接口服抗凝药临床试验中作为排除标准。本研究的目的旨在评估伊多沙班和华法林对房颤伴肝脏疾病史患者的药代动力学(pk)、药效学(pd)、临床疗效和安全性。本ENGAGE AF-TIMI 48临床试验是一项随机双盲对照试验,肝脏疾病史定义为研究者报告的肝病或随机化转氨酶升高2倍以上。在21105名患者中,有1083名(5.1%)患者有肝脏疾病史,他们各种并发症的发生

JACC:粪肠球菌菌血症患者感染性心内膜炎发病率较高

粪肠球菌是导致感染性心内膜炎(IE)第三常见的病原菌。但是目前尚缺乏系统的前瞻性超声心动图研究来检查粪肠球菌菌血症患者的IE患病率。本研究的目的旨在评估IE患者中粪肠球菌菌血症的发病率,次要目的是探索IE的预测因子。本研究纳入分析了344名粪肠球菌菌血症患者(平均年龄74.2岁,男性占73.5%),并对其进行了心超的检测,其中74%患者接受了经食管超声心动图检测。最终有90名患者确诊为IE,发病率

Baidu
map
Baidu
map
Baidu
map